In 2002, Botox Cosmetic was the first FDA-approved neuromodulator intended for use in the aesthetic environment for reduction of lines and wrinkles in the upper face. Similar products, such as Dysport, Xeomin, and Jeuveau, have followed suit, receiving FDA approval for the same aesthetic indications. While there are subtle differences between these products, such as onset and duration, the technology that determines the product’s mechanism of action (how it functions within the body) has remained the same…until NOW.
Daxxify, the new kid on the block, is the latest FDA-approved neuromodulator on the market, boasting unmatched, state-of-the-art technology. What truly sets Daxxify apart, is the utilization of Peptide Exchange Technology which has changed the interaction between the active ingredient, Botulinum Toxin A and the neuronal cell membrane. Extensive cellular and molecular research has demonstrated the benefits of utilizing these novel cell-penetrating peptides, which are essentially short, positively charged, amino-acid sequences.
Benefits include:
· Enhanced binding affinity between Botulinum Toxin A and the neuronal cell membrane,
· Decreased surface absorption of Botulinum Toxin A into the product container and treatment syringe (seen with other neuromodulators)
· Decreased aggregation (or “clumping”) of Botulinum Toxin A
· Improved temperature stability
Additionally, Botox Cosmetic and virtually ALL other neuromodulator products on the market prior to Daxxify, are formulated with human serum albumin, and in some situations, similar animal counterparts, which act as stabilizers and impact how the product functions within the human body. Because PXT eliminates the need for animal or human product stabilizers, Daxxify has become first and only neuromodulator on the market that is consider a vegan product.
Prior to its’ FDA approval, Daxxify underwent rigorous clinical research, namely the largest phase 3 clinical trial of all its neuromodulator counterparts. Clinical research validated not only its’ efficacy, but also its’ safety profile. Perhaps the most exciting finding relates to the product’s longevity. Amongst all 3 clinical trials, Daxxify treatment results lasted on average, 6 months, and in some patients, up to 9 months. Ultimately, patients previously treated every 3 months with neuromodulators other than Daxxify, may experience the same treatment outcomes with ONLY 2 treatments per year!
Skin Appeal is amongst the first practices in Tucson to offer Daxxify as a neuromodulator option, in addition to both Botox Cosmetic and Dysport. For the month of April, Daxxify is being offered at a reduced introductory price! Contact our office today for additional information or to schedule a treatment appointment!
Call (520) 261-7546